Cotellic
Roche’s Tecentriq/Cotellic combo therapy fails to impress in colorectal cancer
May 11, 2018Medical Communications, Research and Development Cancer, Cotellic, Roche, pharma, tecentriq
Roche has been rocked by a Phase 3 weak showing from its combination Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people …
Roche gets a NICE knockback for melanoma drug, Cotellic
June 16, 2016Medical Communications, Research and Development, Sales and Marketing Cotellic, NICE, Roche
The National Institute for Health and Care Excellence (NICE) has announced that that it has not recommended Roche’s melanoma drug, …
FDA approves Roche skin cancer combination
November 11, 2015Research and Development, Sales and Marketing Cotellic, FDA, Genentech, Roche, Zelboraf, cobimetinib, melanoma, skin cancer, vemurafenib
The FDA has approved the skin cancer drug Cotellic for certain forms of melanoma in combination with another Roche cancer …
Latest content
One in three UK women with migraine say symptoms taken less seriously
September 24, 2026
Report highlights scope to expand day surgery
September 23, 2026
Sygnature formalises drug discovery collaboration with X-Chem
September 22, 2026
Codis appoints Steven Facer as chief commercial officer
September 21, 2026
Danish medical cannabis use rises as regulator reports no new safety signals
September 21, 2026
